

1 **Dietary protein source mediates colitis pathogenesis through bacterial modulation of bile**  
2 **acids**

3 Simon M. Gray<sup>1\*</sup>, Michael C. Wood<sup>2\*</sup>, Samantha C. Mulkeen<sup>2</sup>, Sunjida Ahmed<sup>2</sup>, Shrey D.  
4 Thaker<sup>2</sup>, Bo Chen<sup>2</sup>, William R. Sander<sup>2</sup>, Vladimira Bibeava<sup>2</sup>, Xiaoyue Zhang<sup>3</sup>, Jie Yang<sup>4</sup>, Jeremy  
5 W. Herzog<sup>1</sup>, Shiyong Zhang<sup>5</sup>, Belgin Dogan<sup>5</sup>, Kenneth W. Simpson<sup>5</sup>, R. Balfour Sartor<sup>1,6,7</sup> and  
6 David C. Montrose<sup>2,8</sup>

7 <sup>1</sup>Center for Gastrointestinal Biology and Disease, Department of Medicine, University of North  
8 Carolina, Chapel Hill, NC

9 <sup>2</sup>Department of Pathology, Renaissance School of Medicine, Stony Brook University, Stony  
10 Brook, NY

11 <sup>3</sup>Biostatistical Consulting Core, Renaissance School of Medicine, Stony Brook University

12 <sup>4</sup>Department of Family, Population and Preventive Medicine, Stony Brook University, Stony  
13 Brook, NY

14 <sup>5</sup>Department of Clinical Sciences, Cornell University, Ithaca, NY

15 <sup>6</sup>Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC

16 <sup>7</sup>National Gnotobiotic Rodent Resource Center, University of North Carolina, Chapel Hill, NC

17 <sup>8</sup>Stony Brook Cancer Center, Stony Brook, NY.

18 \*Authors contributed equally.

19 **Corresponding Author:** David C. Montrose, Department of Pathology, Renaissance School of  
20 Medicine, Stony Brook University, MART Building, 9M-0816, Lauterbur Dr., Stony Brook, NY  
21 11794. Phone: 631-216-2927; Fax: 631-444-3424; Email:

22 [david.montrose@stonybrookmedicine.edu](mailto:david.montrose@stonybrookmedicine.edu)

23 **Keywords:** Inflammatory bowel diseases; experimental colitis; dietary protein; beef; pea;  
24 interleukin-10 deficient mice; DSS; bile acids; microbiome

25 **Funding:** This work was supported by American Pulse Association and startup funds from the  
26 Stony Brook Cancer Center and Bahl Center for Metabolomics and Imaging (D.C.M.),

27 NIH/NIDDK T32DK007737 (S.M.G., R.B.S.), P01DK094779 (R.B.S.), P40OD010995 (R.B.S.),  
28 P30DK034987 (R.B.S.), Crohn's & Colitis Foundation Gnotobiotic Facility (R.B.S.), UNC  
29 Physician Scientist Training Program Fellowship Award (S.M.G.)

### 30 **Declaration of interests:**

31 D.C.M. has consulting arrangements with Gleipnir Medical. The authors have no other  
32 competing interests relevant to this study.

### 33 **Acknowledgements**

34 The authors thank members of the Montrose and Sartor laboratories for suggestions, helpful  
35 comments, and technical support. We thank Josh Frost, manager of the National Gnotobiotic  
36 Rodent Resource Center, and the Center staff members for gnotobiotic husbandry and mice.  
37 We acknowledge the Biological Mass Spectrometry Shared Resource at the Stony Brook  
38 Cancer Center for expert assistance with the MALDI-MS imaging analysis. We acknowledge the  
39 biostatistical consultation and support provided by the Biostatistical Consulting Core at School  
40 of Medicine, Stony Brook University.

41

### 42 **Introductory paragraph**

43 Evidence-based dietary recommendations for individuals with inflammatory bowel  
44 diseases (IBD) are limited. Red meat consumption is associated with increased IBD incidence  
45 and relapse in patients, suggesting that switching to a plant-based diet may limit gut  
46 inflammation. However, the mechanisms underlying the differential effects of these diets remain  
47 poorly understood. Feeding diets containing plant- or animal-derived proteins to murine colitis  
48 models revealed that mice given a beef protein (BP) diet exhibited the most severe colitis, while  
49 mice fed pea protein (PP) developed mild inflammation. The colitis-promoting effects of BP were  
50 microbially-mediated as determined by bacterial elimination or depletion and microbiota  
51 transplant studies. In the absence of colitis, BP-feeding reduced abundance of *Lactobacillus*  
52 *johnsonii* and *Turicibacter sanguinis* and expanded *Akkermansia muciniphila*, which localized to

53 the mucus in association with decreased mucus thickness and quality. BP-fed mice had  
54 elevated primary and conjugated fecal bile acids (BAs), and taurocholic acid administration to  
55 PP-fed mice worsened colitis. Dietary psyllium protected against BP-mediated inflammation,  
56 restored BA-modulating commensals and normalized BA ratios. Collectively, these data suggest  
57 that the protein component of red meat may be responsible, in part, for the colitis-promoting  
58 effects of this food source and provide insight into dietary factors that may influence IBD  
59 severity.

60

## 61 **Main Text**

62 Diet influences the pathogenesis and natural history of inflammatory bowel diseases  
63 (IBD), disorders of chronic intestinal inflammation caused by dysregulated host immune  
64 responses to resident intestinal microbes in genetically susceptible hosts<sup>1-3</sup>. Despite these  
65 findings, limited evidence-based dietary recommendations exist to reduce the incidence and  
66 severity of IBD<sup>4-6</sup>. For multiple decades IBD incidence has increased in the U.S. and globally,  
67 including in regions with previously low rates<sup>7-9</sup>. Increased animal-based protein consumption,  
68 including red meat, correlates with rising IBD incidence, suggesting a link between animal  
69 protein consumption and IBD<sup>10, 11</sup>. However, the mechanisms by which specific dietary protein  
70 sources promote gut inflammation remains unclear.

71 Diet regulates gut homeostasis and inflammation, in part, by shaping the composition,  
72 function, and metabolic activity of the gut microbiota<sup>2, 12-21</sup>. For example, reducing dietary fiber or  
73 increasing fructose consumption in mice enriches mucus-digesting resident bacteria, such as  
74 *Akkermansia muciniphila*<sup>12, 17-19, 21</sup>. Further, consuming high fructose or dietary milk fat limits the  
75 deconjugation of bile acids (BAs) (small molecules synthesized by the liver and modified by  
76 intestinal microbes), resulting in increased levels of conjugated BAs (CBAs) and exacerbated  
77 experimental colitis<sup>17, 22</sup>. Notably, patients with active IBD have higher levels of primary and  
78 CBAs and depleted secondary unconjugated BAs, relative to healthy controls<sup>23-25</sup>. Moreover,

79 primary CBAs, which are metabolized by microbial enzymes to unconjugated secondary BAs,  
80 exacerbate inflammation in experimental colitis models<sup>22, 24, 26</sup>. However, the role of dietary  
81 protein source in these complex interactions and development of colonic inflammation is poorly  
82 understood.

83 To investigate the impact of dietary protein source on experimental colitis severity, five  
84 isocaloric synthetic diets containing protein isolates from beef, egg whites, casein, soy or pea  
85 (**Table S1**) were fed to wild-type (WT) specific pathogen-free (SPF) C57BL/6J mice during  
86 dextran sodium sulfate (DSS)-mediated induction of colitis. Mice fed beef protein (BP) diet  
87 developed the most severe colitis while those fed pea protein (PP) diet developed the least  
88 severe colitis; egg whites, casein, or soy protein diets induced intermediate colitis severity (**Fig.**  
89 **1A-D**). BP feeding resulted in more severe colitis in a T-cell mediated colitis model using ex  
90 germ-free (GF) *Il10*<sup>-/-</sup> mice colonized with mouse-adapted pooled human IBD microbiota (IMM-  
91 HM2), to induce human IBD microbiota-associated colitis<sup>27</sup>, compared to feeding a PP diet (**Fig.**  
92 **1E-G**). This was characterized by greater weight loss, more severe histologic inflammation and  
93 higher expression of colonic pro-inflammatory cytokines (**Fig. 1E-G**). Similar findings were made  
94 in a second model of human IBD microbiota-associated colitis (IMM-g2)<sup>27</sup> (**Fig. 1H-J**). To  
95 evaluate whether BP promotes colonic inflammation in the absence of a colitis inducer (i.e. DSS  
96 or IBD patient-derived stool), WT SPF mice were fed standard chow, PP diet, or BP diet for 8  
97 weeks and monitored, which showed no significant differences in DAI or colonic pro-  
98 inflammatory cytokine expression (**Fig. S1A-B**). Collectively, these data demonstrate that the  
99 protein component of beef worsens colonic inflammation in multiple experimental colitis models.

100 We next tested whether protein source modulates colitis severity, in part, through gut  
101 resident bacteria. First, WT SPF mice were fed PP diet, BP diet, or BP diet in combination with  
102 broad-spectrum antibiotics in drinking water to globally reduce gut bacteria, then challenged  
103 with DSS while continuing the respective diets and antibiotics. Antibiotic treatment reduced BP  
104 diet-mediated DSS colitis severity to, or below, PP diet-mediated levels (**Fig. 2A-C**). An ~500-

105 fold depletion in total bacterial abundance in feces of mice given antibiotics was confirmed by  
106 qRT-PCR. Next, GF *I110*<sup>-/-</sup> mice were fed BP or PP diets for 14 days and assessed for colonic  
107 inflammation by multiple parameters, which revealed no overt colitis in either group (**Fig. 2D-F**).  
108 GF status in both groups was confirmed by anaerobic culture of feces (data not shown). Lastly,  
109 we performed a fecal microbial transplant phenotype transfer experiment. Here, feces from WT  
110 SPF mice fed BP or PP diets for 1 week were transplanted to GF WT mice fed standard rodent  
111 chow and challenged with DSS for 10 days. Measurements of disease activity index (DAI),  
112 colon length and histologic score showed that mice gavaged with fecal slurry from BP-fed mice  
113 developed more severe colitis than mice administered feces from PP-fed mice (**Fig. 2G-I**).  
114 Together, these data demonstrate that BP exacerbates colitis through the diet-altered  
115 microbiota.

116         Since the dietary protein-altered microbiota mediates colitis severity, bacterial  
117 community composition was profiled by 16S rRNA amplicon sequencing of feces from SPF WT  
118 mice fed BP or PP diets for 1 week in the absence of colitis. Principal coordinates analysis  
119 demonstrated distinct clustering of mice according to dietary protein source, which explained  
120 approximately 65% of variation in the data (PERMANOVA test coefficient of determination,  $R^2 =$   
121 0.43,  $p=0.005$ ) (**Fig 3A**). Although profiles before feeding either experimental diet were very  
122 similar, 7 days of feeding BP or PP diet significantly altered the taxonomic abundance of  
123 multiple bacteria (**Fig 3B; Fig. S2**). Significant expansion of *Akkermansia muciniphila* occurred  
124 in the BP diet group, while *Turicibacter sanguinis* increased in the PP diet group, along with  
125 preservation of *Lactobacillus johnsonii* (**Fig. 3B-C**). *A. muciniphila* can impair gut barrier function  
126 through mucus digestion<sup>12, 17, 21, 28-30</sup>, therefore, we examined its colonic luminal spatial  
127 distribution by fluorescence *in situ* hybridization (FISH). This revealed high abundance of *A.*  
128 *muciniphila* adjacent to the mucus layer of BP-fed mice while no signal was observed in PP-fed  
129 mice (**Fig. 3D**). Colonic surface mucus thickness showed a corresponding ~50% reduction in  
130 BP vs. PP fed mice (**Fig. 3E**). Additionally, surface mucus quality was reduced in BP- vs. PP-fed

131 mice with no obvious difference in goblet cell mucus staining (**Fig. 3F; Fig. S3**). To evaluate  
132 whether BP-driven expansion of *A. muciniphila* was responsible, in part, for promoting colitis,  
133 GF *Il10*<sup>-/-</sup> mice were selectively colonized with *A. muciniphila* alone, a consortium of IBD-  
134 associated pathobionts including *Escherichia coli*, *Enterococcus faecalis*, and *Ruminococcus*  
135 *gnavus* (EER), or *A. muciniphila* plus EER and fed BP diet. Although *A. muciniphila* mono-  
136 association did not induce colitis, it significantly potentiated EER pathobiont-induced colitis  
137 severity (**Fig 3G-H**). Appropriate strain colonization was confirmed by anaerobic plating of feces  
138 from colonized mice followed by 16S colony PCR and Sanger sequencing of representative  
139 colony morphologies (data not shown). These data suggest that BP exacerbates colitis, in part,  
140 by promoting expansion of mucus-digesting *A. muciniphila* that potentiates the pro-inflammatory  
141 effects of IBD-associated pathobionts.

142 Because bacteria have an important role in mediating BA metabolism and composition  
143 and there was higher abundance of bile salt hydrolase (BSH)-carrying<sup>31-34</sup> bacteria (*T sanguinis*,  
144 *L johnsonii*) in PP-fed mice, we next measured the relative levels of common BAs in feces from  
145 WT SPF mice fed BP or PP diets for 7 days in the absence of colitis. This analysis showed that  
146 most BAs in BP-fed mice were primary and conjugated while most BAs in PP fed mice were  
147 secondary and unconjugated (**Fig. 4A**). Multiple taurine conjugated primary BAs, including  
148 taurocholic acid (TCA), were significantly higher in BP-fed mice while several unconjugated  
149 secondary BAs, including lithocholic acid (LCA) and deoxycholic acid (DCA), were elevated in  
150 PP-fed mice (**Fig. 4B**). These patterns were not observed in the livers or ileal content of mice  
151 fed BP vs. PP diets (data not shown), suggesting that fecal BA alterations are likely mediated by  
152 colon-specific microbial differences. To connect the respective BA profiles of mice fed PP or BP  
153 diets with differential bacterial abundance, we performed an *in vitro* bile acid deconjugation  
154 assay comparing select bacterial species enriched by either diet. This revealed that *L. johnsonii*  
155 (higher abundance in PP-fed mice) deconjugated TCA to cholic acid (CA) 100-fold more than *A.*  
156 *muciniphila* (increased in BP-fed mice) (**Fig. 4C**). To evaluate whether the primary CBAs that

157 were increased in feces of BP diet-fed mice directly exacerbate colitis, PP-fed mice were  
158 administered TCA by oral gavage daily for 7 days and exposed to DSS. DAI, colon length and  
159 histologic score showed that TCA worsened colitis in PP-fed mice (**Fig 4D-F**). Subsequent  
160 MALDI-MSI based imaging of the colon of mice administered TCA in the absence of colitis  
161 revealed TCA accumulation in the colonic epithelium (**Fig. S4**). Collectively, these data suggest  
162 that mice consuming a BP-containing diet have lower abundance of BA-deconjugating bacteria,  
163 resulting in higher levels of colitis-promoting primary CBAs.

164         Microbe-accessible dietary fiber supports populations of gut health-promoting  
165 commensals, including BA-metabolizing bacteria<sup>35</sup>. Therefore, we reasoned that maintaining  
166 these bacterial populations by adding soluble dietary fiber would attenuate BP-driven colitis  
167 severity. To test this concept, ex-GF *I110*<sup>-/-</sup> mice inoculated with MA human IBD microbiota were  
168 fed PP diet, BP diet, or BP diet in which cellulose fiber was replaced with psyllium (BP-psyllium  
169 diet) and monitored for colitis severity (**Table S1**). Compared to BP diet, the BP-psyllium diet  
170 significantly decreased colitis severity, as determined by body weight, fecal lipocalin, histologic  
171 analysis and cytokine gene expression (**Fig. 4G-J**). Similar protection by psyllium was observed  
172 in the DSS-induced colitis model (**Fig. S5**). Analysis of BA-metabolizing bacteria and BA profiles  
173 in WT C57BL/6J mice fed each of these three diets in the absence of colitis showed that  
174 psyllium supplementation significantly increased the relative abundance of *L. johnsonii* and the  
175 CA:TCA ratio in BP-fed mice (**Fig. 4K-L**). Taken together, these data support a model in which  
176 BP-exacerbated colitis, which is driven by high abundance of primary CBAs, can be attenuated  
177 through psyllium fiber administration, restoring populations of BSH-carrying bacteria that convert  
178 primary CBAs to their deconjugated form.

179         Plant-based diets are believed to benefit IBD patients, while animal-based diets may be  
180 detrimental. Both retrospective and prospective studies suggest that consumption of red meat is  
181 associated with IBD incidence and disease activity. For example, The E3N Prospective Cohort  
182 Study revealed that high animal protein consumption significantly increased IBD incidence<sup>36</sup> and

183 multiple studies showed that meat intake increased the risk of disease flare in patients with  
184 ulcerative colitis (UC)<sup>5, 37, 38</sup>. The concept that plant-based diets are beneficial largely stems from  
185 studies demonstrating that microbe-fermentable carbohydrates from plants reduce experimental  
186 colitis<sup>2, 39</sup>. In contrast, diets rich in animal-derived products (especially red meat) are thought to  
187 promote intestinal inflammation through heme, sulfur and saturated fat content<sup>2, 39</sup>. Although  
188 these components of plant and animal-based diets impact gut health, the role of protein content  
189 has not been widely considered. Our study, which selectively examined protein content by  
190 feeding mice identical diets except for the type of protein isolate, suggests that the source of  
191 dietary protein content differentially impacts colitis severity. Other studies investigating the  
192 impact of protein source on experimental colitis, including from beef and pea, are largely  
193 consistent with the data shown in the current study, although this previous work used diets  
194 containing whole food sources rather than purified protein isolate<sup>14, 15, 40, 41</sup>. Our findings support  
195 a role for the dietary protein-altered microbiota and BAs in mediating colitis severity, however,  
196 the specific mechanism(s) by which protein type drives these effects remains unclear. It is  
197 plausible that differences in amino acid composition or digestion/absorption of diverse dietary  
198 protein sources are contributing factors. Therefore, determining which amino acids or what  
199 properties of each protein type mediate intestinal inflammation will be important for future  
200 studies.

201 Bacteria, BAs and their interplay are key mediators of IBD pathogenesis<sup>1, 2</sup>. Higher levels  
202 of conjugated and primary BAs are found in feces of patients with active IBD, compared to  
203 unconjugated and secondary BAs in healthy individuals<sup>23-25</sup>. Our work suggests that a shift to a  
204 predominance of conjugated and primary BAs, is in part, responsible for greater colitis severity  
205 when feeding BP to mice. We found that taurine conjugated and primary BAs are higher in BP-  
206 fed mice than PP-fed mice, and showed that direct administration of TCA, which was highly  
207 increased in the BP-fed group, worsened colitis in PP-fed mice to levels observed in mice given  
208 BP diet alone. Although the exact mechanism(s) by which altered BAs enhance disease is

209 unclear, the detergent-like properties of BAs could disrupt gut barrier function by impairing  
210 epithelial cell function and/or epithelial-protective mucus. This concept is supported by our data  
211 showing the ability of exogenously administered TCA to localize to the colonic epithelium.  
212 Interestingly, our prior work showed that a high fructose diet exacerbated murine colitis with a  
213 similar increase in CBAs as observed in BP fed mice, with rectal administration of CBAs  
214 worsening colitis and thinning colonic mucus in mice fed a control diet<sup>17</sup>. Integrating our study  
215 focused on dietary protein with prior studies of the role of dietary fat and carbohydrates in  
216 experimental colitis suggests that altered BAs may be a common pathway for diet-mediated gut  
217 inflammation<sup>17, 22</sup>. Although our work focused on the detrimental impact of conjugated primary  
218 bile acids enriched in BP-fed mice, the profile of unconjugated, secondary bile acids enriched in  
219 feces from PP fed mice might itself be protective. For example, LCA and DCA, both enriched in  
220 PP-fed mice, are strong ligands of the PXR and TGR5 receptors that, when activated, induce  
221 anti-inflammatory effects<sup>24, 42-44</sup>. Therefore, the role of unconjugated secondary bile acids as  
222 protective metabolites in PP-fed mice is an important future direction.

223 Bile acids have a bidirectional relationship with gut bacteria, whereby bacterial enzymes  
224 metabolize BAs, which in turn, alter bacterial physiology and microbiota composition<sup>42</sup>. PP  
225 feeding expanded bacterial species that efficiently deconjugate BAs, including *L johnsonii* and *T*  
226 *sanguinis* (as shown by data from the deconjugation assay performed in the current study and  
227 previous work<sup>32</sup>), while BP feeding expanded *A muciniphila*, a poor deconjugator that also  
228 degrades mucus and potentiates pathobiont-driven inflammation<sup>45</sup>. These dietary protein-  
229 induced bacterial shifts likely caused the observed BA profiles, however, we cannot exclude the  
230 possibility that altered BAs directly shifted microbiota composition, as previously  
231 demonstrated<sup>46-49</sup>. Further evidence that the ratio of conjugated to unconjugated BAs are  
232 important for mediating colitis stems from our findings that psyllium supplementation protected  
233 against BP-mediated colitis severity, while maintaining favorable BA profiles and populations of  
234 BA-deconjugating bacteria. However, psyllium fiber likely protects against inflammation by

235 multiple mechanisms, including SCFA production and prevention of bacterial mucus  
236 degradation<sup>12, 50</sup>.

237 Our study reaffirms the concept that IBD occurs when multiple detrimental factors  
238 intersect to initiate and perpetuate gut inflammation<sup>51</sup>. These IBD determinants – genetically  
239 dysregulated host inflammatory and epithelial barrier responses, abnormal resident microbes,  
240 and environmental triggers – can exist in isolation or combination without causing disease, but  
241 together drive severe IBD. For example, GF colitis susceptible *I110*<sup>-/-</sup> mice fed BP diet (genetic  
242 susceptibility + environmental trigger) did not develop inflammation, nor did SPF WT mice fed  
243 BP-diet (resident microbes + environmental trigger). However, we demonstrated that when all  
244 three IBD-driving factors – host, microbe, and environment – intersect, severe and progressive  
245 intestinal inflammation occurs. The poor long-term success of current human IBD therapies may  
246 reflect a failure to reconcile the multiple determinants of IBD. For example, addressing just one  
247 factor, such as suppression of host inflammation, leaves the patient vulnerable to recurrent  
248 disease upon encountering environmental triggers. We suggest that durable long-term  
249 remission requires simultaneously addressing all IBD determinants, and as such, investigations  
250 into environmental drivers of IBD, especially diet, is required to guide clinical approaches to  
251 maintain sustained remission.

252

## 253 **Methods**

### 254 *Murine colitis models*

255 To induce chemical colitis, 8-week-old male C57BL/6J mice (The Jackson Laboratory)  
256 were administered 1% DSS (Sigma) in drinking water for 6–7 days, as indicated. Colitis severity  
257 was assessed by measuring changes in body weight, as well as severity of rectal bleeding and  
258 diarrhea, as previously described<sup>17, 52</sup>. Disease Activity Index (DAI) was calculated by combining  
259 severity of body weight loss, diarrhea and bleeding, as previously described<sup>17, 52</sup>.

260 T cell-mediated colitis was induced by inoculation of mouse-adapted human IBD patient  
261 fecal microbiota (previously developed and characterized<sup>27</sup>) to GF *Il10*<sup>-/-</sup> mice on a 129S6/SvEv  
262 background (purchased from the National Gnotobiotic Rodent Resource Center (NGRRC) at the  
263 University of North Carolina), as previously described<sup>27</sup>. Mouse-adapted (MA) human IBD  
264 patient microbiota was previously generated from de-identified human IBD patient stool samples  
265 collected under an Institutional Review Board approved protocol; no primary human samples  
266 were used in this study<sup>27</sup>. Briefly, human fecal materials from pooled cohorts of human donors  
267 with active IBD were passaged through GF 129S6/SvEv *Il10*<sup>-/-</sup> mice to generate standardized  
268 aliquots of fecal slurry<sup>27</sup>. MA IMM-g2 microbiota was derived from pooled feces of 2 CD and 1  
269 UC patient and MA IMM-HM2 microbiota was derived from pooled feces of 3 CD patients<sup>27</sup>.  
270 Standardized 100mg/ml aliquots of mouse-adapted human IBD microbiota were anaerobically  
271 thawed, diluted with pre-reduced PBS, and administered by oral gavage (2mg) to recipient GF  
272 *Il10*<sup>-/-</sup> mice<sup>27</sup>. All fecal transplant experiments were performed with sterile gnotobiotic cage  
273 technique in BSL-2 isolation cubicles with HEPA-filtered air<sup>53</sup>. Prior to colonization, GF mice  
274 were fed Purina Advanced Protocol Select Rodent 50 IF/6F Auto Diet. Defined diets were  
275 started at the time of fecal microbiota transplant.

276 At the end of the experimental periods, mice were humanely euthanized using CO<sub>2</sub>.  
277 Excised colons were measured then flushed with ice-cold phosphate-buffered saline (PBS).  
278 Tissue was either snap-frozen for biochemical analysis or fixed in 4% paraformaldehyde or 10%  
279 phosphate buffered formalin for 4-24 hours, followed by paraffin embedding and H&E staining  
280 for histological analysis. All animal studies were approved by the Institutional Animal Care and  
281 Use Committee at Stony Brook University and the University of North Carolina at Chapel Hill.

282

### 283 *Diet-polarized fecal microbiota transplant (FMT)*

284 Feces were collected from WT C57BL/6J SPF mice fed BP or PP diets for 2 weeks,  
285 anaerobically homogenized, and diluted in pre-reduced lysogeny broth (LB) with 20% glycerol to

286 generate fecal slurries (n=5-6 donor mice per diet). Each donor FMT was administered to 1-2  
287 recipient mice GF C57BL/6J mice via oral gavage on days 0, 3, 5, 7, and 9 of the experiment.  
288 Mice were administered 2% DSS from days 3-10 of the experiment and monitored for signs of  
289 colitis.

290

#### 291 *Inoculation of defined consortia*

292 *Escherichia coli* LF82<sup>54</sup>, *Enterococcus faecalis* OG1RF<sup>55</sup>, and *Ruminococcus gnavus*  
293 ATCC 29149<sup>55</sup> (EER) were grown under anaerobic conditions in brain-heart infusion medium  
294 supplemented with 5g/L yeast extract, 0.5g/L L-cysteine, and 5mg/L hemin (LYH-BHI medium).  
295 *A. muciniphila* ATCC BAA-835 (AM) was grown under anaerobic conditions in LYH-BHI medium  
296 supplemented with 5g/L porcine gastric mucin (LYH-BHI + PGM). Pure cultures of each strain  
297 were grown anaerobically to confluence then equally mixed to generate EER or EER + AM  
298 consortia. GF 129S6/SvEv *Il10*<sup>-/-</sup> mice were colonized with freshly cultured consortia by oral  
299 gavage and given BP diet from the time of colonization. Feces were collected at necropsy, serial  
300 diluted and plated under anaerobic conditions on LYH-BHI + PGM to confirm colonization with  
301 consortia members. Representative colonies of each strain identified by colony morphology  
302 were picked from plates, 16S PCR amplified, and Sanger sequenced (Eton Bioscience) to  
303 confirm colonization of appropriate strains in recipient mice.

304

#### 305 *Histopathologic scoring*

306 Colons from mice given DSS were flushed, formalin fixed, and paraffin embedded  
307 followed by sectioning and staining with hematoxylin and eosin. Scoring of colitis/colonic  
308 inflammation was performed based on evaluation of mucosal damage by acute inflammation, by  
309 crypt abscess, mucosal architectural distortion and proportion of the involvement of colon as  
310 previously described<sup>56</sup>. Briefly, epithelial damage by acute inflammation was graded into 4  
311 categories (0-3; 0=no inflammation. 1=mild, 2=moderate and 3=severe inflammation with

312 ulceration). Mucosal damage with crypt abscess graded into 2 categories (0=absent and  
313 1=present). Extent of acute inflammation was graded into 4 categories (0-3; 0=no inflammation,  
314 1=mucosal, 2=submucosal and 3=transmural). Mucosal architectural distortion was graded into  
315 4 categories which includes the percentage of length of colon involvement (0-3; 0=normal  
316 architecture, 1= mild/focal or 10%, 2=moderate/20-30%, and 3=severe/ >40% of the entire  
317 length). Proportion of the total involvement was evaluated by the percentage of length of colon  
318 involved by colitis into 4 categories (0-3; 0=no colitis, 1=1-10% of the total length, 2=20-30%  
319 and 3=>40% of the total evaluated length of colon). All histologic scoring was performed in a  
320 blinded fashion by a board-certified gastrointestinal pathologist (S.A.).

321 For *Il10<sup>-/-</sup>* experimental colitis studies, histologic inflammation was quantified in ileal,  
322 cecal and colonic (proximal, distal, rectal) tissue segments using a well-validated rubric by  
323 blinded histopathology scoring on a scale of 0-4 for each segment, as previously described<sup>27, 56,</sup>  
324 <sup>57</sup>. Total histology score was calculated by summation of all 5 tissue segment scores for a scale  
325 of 0-20.

326

### 327 *Fecal lipocalin-2 quantification*

328 Fecal samples were homogenized in PBS with 0.1% Tween 20, incubated at 4°C for 12  
329 hours, then centrifuged to yield clear supernatant for lipocalin-2 ELISA, performed according to  
330 the manufacturer's instructions (DY1857, R&D Systems)<sup>58</sup>.

331

### 332 *Measurements of mucus thickness and quality*

333 Segments of harvested colons from mice containing a fecal pellet were preserved in  
334 fresh Carnoy's fixative solution (methanol:chloroform:glacial acetic acid, 60:30:10) then  
335 sequentially washed in methanol, ethanol and xylenes, as previously described<sup>17</sup>. Tissues were  
336 then paraffin-embedded and sectioned (5 µm), followed by staining with Alcian Blue, and mucus

337 thickness was measured in 20-50 regions of each colon in a blinded manner using ImageJ  
338 software (National Institutes of Health, Bethesda, MD), as previously described<sup>17</sup>.

339 To determine differences in mucus quality on the surface of the epithelium and within  
340 goblet cells, Periodic acid Schiff (PAS) staining was performed. Stained slides were scanned  
341 using an Aperio Image Scope (ScanScope, Aperio, CA) and used to count the PAS-positive  
342 pixels by the Aperio Color Deconvolution algorithm, as previously described<sup>17</sup>.

343

#### 344 *qRT-PCR*

345 For measurements of mammalian gene expression, RNA was isolated from tissues  
346 using QIAzol Lysis Reagent (Qiagen) following the manufacturer's protocol. RNA concentration  
347 was measured using a NanoDrop ND-1000 spectrophotometer. cDNA was synthesized using  
348 2000 ng total RNA and reverse transcriptase qScript SuperMix (Quanta). Quantitative real-time  
349 PCR was performed using specific primers on a QuantStudio 7 Real-Time PCR System  
350 (Applied Biosystems) using PowerTrack SYBR Green PCR Master Mix and oligo (dT) primers  
351 according to the user's manual. *Actb* expression was used as internal control for gene  
352 expression. The  $\Delta\Delta CT$  method was used to calculate relative fold expression. Primer  
353 sequences are shown in **Table S2**.

354 For bacterial abundance and bacterial gene expression analysis, DNA was extracted  
355 from fecal samples using the QIAamp DNA Fast Stool Mini Kit (Qiagen) per the manufacturer's  
356 instructions. For each sample, 10 ng of DNA was used for qRT-PCR using PowerTrack SYBR  
357 green PCR master mix on a QuantStudio 7 PCR Machine. Bacterial primers sequences are  
358 shown in **Table S2**. Relative abundance was calculated by the  $\Delta\Delta CT$  method using universal  
359 16S primers as control.

360

#### 361 *Bile acid analysis*

362 Fecal and ileal samples were dried in a vacuum centrifuge then homogenized in 500  $\mu$ L

363 of cold 80% methanol. Liver samples were homogenized using the same method but without  
364 prior drying. Bacterial supernatants were mixed with cold 80% methanol in a 1:9 ratio. Following  
365 homogenization or mixing, samples were centrifuged at 14,000 rcf for 20 minutes at 4°C and the  
366 supernatant was collected and dried down using a vacuum centrifuge then stored at -80° C prior  
367 to analysis. Bile Acid analysis was performed as previously described on a Vanquish UHPLC  
368 system coupled to a Q Exactive Orbitrap mass spectrometer (Thermo Scientific)<sup>17</sup>.  
369 Relative quantitation was normalized to dry weight of fecal/ileal samples or protein  
370 concentration of livers. Analysis was performed at the Proteomics & Metabolomics Core Facility  
371 of Weill Cornell Medicine.

372

### 373 *MALDI Mass Spectrometry Imaging*

374 Tissue preparation and imaging was performed following a previously published  
375 method<sup>59</sup>. Briefly, mouse colons were processed into Swiss-rolls, embedded in 5%  
376 carboxymethylcellulose, and stored at -20°C. Serial frozen sectioning was performed for paired  
377 MALDI imaging and standard H&E staining. MALDI imaging was conducted on a rapifleX mass  
378 spectrometer (Bruker Daltonics) within metabolite mass range in negative ion detect mode at 50  
379 µm spatial resolution. The TCA deprotonated ion with a mass-to-charge ratio of 514.284 m/z  
380 was detected, and the average intensity of the mass spectrometry signal for TCA determined  
381 using SCiLS Lab software (Bruker Daltronic).

382

### 383 *16S rRNA Analysis*

384 Frozen fecal samples were shipped to Molecular Research (Shallowater, TX) for 16S  
385 rRNA profiling, performed as previously described<sup>17</sup>. DNA was extracted with the Powersoil  
386 DNA Kit (Qiagen). The 16S rRNA gene V4 variable region was targeted for PCR amplification,  
387 followed by Illumina HiSeq short-read sequencing. Sequencing outputs were processed and  
388 taxonomically classified as previously described<sup>17</sup>. Operational taxonomic units were defined by

389 clustering at 97% similarity (3% divergence) and classified by BLASTn against an RDPII/NCBI  
390 derived database. Statistical analysis and visualization of principal coordinates analysis (PCoA)  
391 plots were performed with the Shiny application *Plotmicrobiome* (Sun et al. GitHub  
392 <https://github.com/ssun6/plotmicrobiome>).

393

#### 394 *Fluorescence in situ hybridization (FISH)*

395 Fluorescence in situ hybridization (FISH) was performed as previously described<sup>17, 60</sup> on  
396 4µm histologic sections of Carnoy's-fixed paraffin-embedded colon tissue using an *A.*  
397 *muciniphila*-specific FISH probe (S-SMUC-1437-a-A-20: Cy-3-50-  
398 CCTTGCGGTTGGCTTCAGAT-30)<sup>17, 60</sup>. Slides spotted with multiple control bacteria (*E. coli*, *P.*  
399 *vulgaris*, *K pneumoniae*, *S equi*, *S bovis*) not-reactive to the A.M. FISH probe were used to  
400 confirm probe specificity<sup>17, 60</sup>.

401

#### 402 *In vitro bacterial culture and treatment*

403 *L. johnsonii* BAA-3147 and *A. muciniphila* BAA-835 from frozen stocks were cultured  
404 overnight in MRS or LYH-BHI + 0.5% mucin, respectively, the day before the experiments. *A.*  
405 *muciniphila* BAA-835 was cultured in an anaerobic chamber (Coy Laboratory) with mixed gas  
406 (90% N<sub>2</sub>, 5% CO<sub>2</sub> and 5% H<sub>2</sub>; 37°C), and *L. johnsonii* BAA-3147 was cultured under aerobic  
407 conditions (37°C with shaking at 150 rpm). The overnight cultures were diluted with fresh media  
408 with or without 1 mM taurocholate to *A. muciniphilla* BAA-835 (once at OD600 of 1-1.1) and to  
409 *L. johnsonii* (once at OD600 of 0.7-0.8). The diluted cultures were immediately distributed into  
410 two sets of tubes for 0 and 24 h time points, each in triplicate. The time 0 h samples were  
411 transferred to ice immediately to prevent bacterial activity on taurocholate. Optical densities  
412 were measured at each time point for normalization. The cultures were then centrifuged at  
413 3,000 rpm for 20 min at 4°C and the supernatants were filtered through a 0.2 µm syringe filter  
414 and kept at -80°C until BA measurements.

415

## 416 *Statistical analysis*

417 For the comparison of DAI across different mice groups, linear mixed-effects models for  
418 longitudinal data analysis were used. Model assumption was confirmed using residual  
419 diagnosis. Time (in days) was treated as a continuous variable to assess the trend in DAI. An  
420 interaction term between diet group and time was used to compare the trends across groups.  
421 The covariance structure used to model the correlated longitudinal measurements from the  
422 same mice was unstructured (UN), selected based on Akaike Information Criterion (AIC) from a  
423 set of possible structures. For the comparison of numeric values observed or calculated at the  
424 end of experiments, Wilcoxon rank-sum tests or simple linear regression models were used.  
425 These analyses were applied to the following variables: % body weight change, histology score,  
426 gene expression, colon length, bacterial abundance, mucus thickness, mucus quality, and bile  
427 acid ratios. A P-value less than 0.05 was considered statistically significant and analyses were  
428 performed using SAS 9.4 (SAS Institute Inc., Cary, NC).

429 Statistical analysis of BA levels. The BA dataset was filtered to remove BA with >50%  
430 missing values. Normalization of raw metabolite levels was performed by probabilistic quotient  
431 normalization followed by log<sub>2</sub>-transformation and imputation of missing values by k-nearest  
432 neighbor (KNN). BA differences were quantified by log<sub>2</sub> fold change from the PP diet group.  
433 Linear models with diet as the independent variable were used to calculate statistical  
434 significance. The Benjamini-Hochberg method with an FDR cut-off of 0.2 was used for multiple  
435 hypothesis correction. Analyses were performed with the maplet package (version 1.2.1) in R<sup>61</sup>.

436

## 437 **Figure Legends**

### 438 **Figure 1. Dietary beef protein worsens murine colitis compared to other protein sources**

439 A-D, C57BL/6 mice were fed isocaloric diets containing protein isolate derived from beef (BP),  
440 soy (SP), egg whites (EP), casein (CP), or pea (PP) for 7 days, followed by administration of 1%

441 DSS for 7 days, while being continued on the respective diets. Disease activity index (DAI) was  
442 measured during DSS exposure (A), percent of body weight change relative to day 0 of DSS  
443 exposure was calculated following 7 days of DSS administration (B) and histologic score was  
444 assessed in colons on day 7 of DSS administration (C). n = 6 mice per group. Representative  
445 histologic images of colons from BP or PP-fed mice are shown (D). E-G, germ-free *Il10<sup>-/-</sup>* mice  
446 were inoculated with mouse-adapted (MA) pooled human IBD patient fecal microbiota (IMM-  
447 HM2) then fed diets containing BP or PP for 14 days. Weight change relative to day 0 was  
448 measured (E), representative histologic images of colons are shown (left side) and total  
449 histology score was assessed (right side) (F), and relative gene expression of cytokines were  
450 measured in colons (G), on day 14. n = 7-8 mice per group. H-J, germ-free *Il10<sup>-/-</sup>* mice were  
451 inoculated with a second MA pooled human IBD patient fecal microbiota (IMM-g2) then fed BP  
452 or PP diets for 8 days. Weight changes relative to day 0 were measured (H), representative  
453 histologic images of colons are shown (left side) and rectal histology score was assessed (right  
454 side) (I), and relative gene expression of cytokines were measured in colons (J), on day 8. n =  
455 4-6 mice per group. Data representative of 3 (E-G), and 3 (H-J) independent experiments.  
456 \*P<0.05; \*\*P<0.01; \*\*\*P<0.001; \*\*\*\*P<0.0001. Bar plots show mean and standard deviation.

457

## 458 **Figure 2. Gut bacteria are causally linked to beef protein-worsening of colitis**

459 A-C, C57BL/6J mice were fed beef protein (BP) or pea protein (PP)-containing diets or beef  
460 protein diet and administered a five-antibiotic cocktail (ampicillin, gentamicin, metronidazole,  
461 neomycin, vancomycin<sup>17</sup>) in drinking water for 14 days (BP + Abx), then all mice were given 1%  
462 DSS in drinking water for 7 days while being continued on control or antibiotics-containing  
463 water. Disease Activity Index (DAI) was measured during DSS exposure (A), colon length was  
464 measured on day 7 (B) and histologic inflammation of colons was assessed on day 7 (C). n = 8  
465 mice per group. D-F, germ-free *Il10<sup>-/-</sup>* mice were fed sterile BP or PP diets for 14 days.  
466 Representative histologic images of colons are shown (D), histology score was assessed (E)

467 and relative gene expression of *Ilf1b* was measured in colons (F), on day 14. n = 4-5 mice per  
468 group. G-I, germ-free wild-type mice were inoculated with colonic luminal fecal contents of  
469 specific pathogen-free mice fed BP or PP diets for 7 days. Recipient mice were then fed  
470 standard chow and administered 1% DSS for 7 days and DAI was calculated (G), colon length  
471 was measured (H) and histologic inflammation of colons was assessed (I), on day 10. n = 9-10  
472 per group; data are representative of 2 independent experiments. \*P<0.05; \*\*P<0.01;  
473 \*\*\*P<0.001; \*\*\*\*P<0.0001. Bar plots show mean and standard deviation.

474

475 **Figure 3. Beef protein consumption promotes *A. muciniphila* expansion and gut barrier**  
476 **defects**

477 A-C, C57BL/6J mice were fed either beef protein (BP) or pea protein (PP)-containing diets for 7  
478 days then fecal samples were subjected to 16S rRNA sequencing. Results are displayed as  
479 principal coordinate analysis on day 7 (A) and as percent abundance of each species on days 0  
480 and 7 (B) (those species <1% in overall abundance are labeled as 'Other'). qRT-PCR was  
481 performed on fecal DNA to measure relative abundance of major populations found in either diet  
482 group (C). D-F, C57BL/6J wild-type mice were fed BP or PP diets for 7 days then colons were  
483 harvested and fixed to preserve the mucus layer. Fluorescence *in situ* hybridization was  
484 performed to identify *A. muciniphila* (indicated by orange structures) (D), Alcian blue staining  
485 was carried out to measure mucus thickness (representative images shown on left side and  
486 quantification of staining shown on right side; bracket indicates mucus layer on images) (E), and  
487 periodic acid Schiff staining was performed to quantify mucus quality (representative images  
488 shown on left side and quantification of staining shown on right side) (F). n = 6 per group. G-H,  
489 germ-free *Ilf10<sup>-/-</sup>* mice were inoculated with *A. muciniphila*, a defined consortium of *Escherichia*  
490 *coli*, *Enterococcus faecalis*, and *Ruminococcus gnavus* alone or in combination with *A.*  
491 *muciniphila* and fed BP diet. Representative histologic images of ceca are shown (left side) and  
492 total histology score was assessed (right side) (G) and relative expression of inflammatory

493 cytokine genes was measured (H) in the ceca of mice on day 14. n = 7-9 per group, data  
494 representative of 2 independent experiments. \*P<0.05; \*\*P<0.01; \*\*\*P<0.001; \*\*\*\*P<0.0001. Bar  
495 plots show mean and standard deviation.

496

#### 497 **Figure 4. Bacteria-mediated bile acid changes facilitate colitis severity**

498 A-B, WT C57BL/6J mice were fed diets containing either beef protein (BP) or pea protein (PP)-  
499 containing diets for 7 days and the relative abundance of bile acids was measured in feces. The  
500 average percent of primary vs. secondary or conjugated vs. unconjugated bile acids in each diet  
501 group is shown (A) and those BAs that displayed significantly different abundance (FDR<0.1)  
502 are shown as log<sub>2</sub> fold-change in PP-fed mice relative to BP-fed mice (B). C, taurocholic acid  
503 (TCA) (1mM) was administered to culture medium of *L. johnsonii* and *A. muciniphila* and the  
504 levels of cholic acid were measured in the supernatants after 24 hours and reported as relative  
505 to either species cultured in the absence of TCA. D-F, C57BL/6J WT mice were fed either BP or  
506 PP diets and given daily oral gavage of PBS or fed PP and gavaged daily with TCA (0.35mg/kg)  
507 for 7 days, then administered 1% DSS in drinking water for 7 days, while continuing oral  
508 administration. Disease Activity Index (DAI) was measured over 7 days (D), colon length was  
509 measured on day 7 (E) and histologic inflammation of colons was assessed on day 7 (F). G-J,  
510 germ-free *Il10*<sup>-/-</sup> mice were inoculated with mouse-adapted pooled human IBD patient fecal  
511 microbiota (IMM-HM2) then fed BP or PP diets containing cellulose or BP diet containing  
512 psyllium (BP + psyllium) for 14 days. Weight changes relative to day 0 were calculated (G),  
513 fecal lipocalin-2 (f-Lcn) was measured (H), total histology score was assessed (I), and relative  
514 gene expression of inflammatory cytokines in colons was measured (J), on day 14. n = 10-11  
515 mice per group. K-L, WT specific pathogen-free mice were fed the diets described in panel G for  
516 7 days and feces were collected to measure the relative abundance of *L. johnsonii* by qRT-PCR  
517 (K) and the ratio of cholic acid to taurocholic acid (CA:TCA) in fecal samples (L). n = 10-11 mice

518 per group. \*P<0.05; \*\*P<0.01; \*\*\*P<0.001; \*\*\*\*P<0.0001. Bar plots show mean and standard  
519 deviation.

520

## 521 **Supplementary Figure Legends**

522 **Figure S1. Long-term beef protein feeding in specific pathogen free wild-type mice does**  
523 **not induce signs of colitis.** Mice were fed chow, or purified diet containing beef protein (BP) or  
524 pea protein (PP) isolate for 8 weeks. Disease activity index (DAI) was measured weekly (A) and  
525 relative expression of *Tnfa* and *I11b* was measured in colons at the end of the study (B). n = 6  
526 mice per group. Bar plots show mean and standard deviation.

527

528 **Figure S2. Relative bacterial species abundance of individual mice fed beef or pea**  
529 **protein-containing diets.** Species abundance in feces from individual mice is reported prior to  
530 (A) and 7 days following (B) administration of diets containing beef protein (BP) or pea protein  
531 (PP) isolate. Those species appearing in abundance <1% in all conditions are labeled as  
532 'Other'.

533

534 **Figure S3. Dietary protein source does not affect goblet cell mucus quality.** C57BL/6J  
535 mice were fed either beef protein (BP) or pea protein (PP)-containing diets for 7 days then  
536 periodic acid Schiff staining was performed to quantify mucus quality within goblet cells.  
537 Representative images (A) and quantification of staining (B) are shown. Bar plots show mean  
538 and standard deviation.

539

540 **Figure S4. Taurocholic acid localizes to the colonic epithelium following oral**  
541 **administration to mice.** C57BL/6J WT mice were administered daily oral gavage of PBS or  
542 taurocholic acid (TCA) (0.35mg/kg) for 7 days and colon tissue sections were subjected to  
543 MALDI-MSI to determine localization (A) and relative abundance (B) of TCA in each group. TCA

544 group is normalized to vehicle group in panel B. n = 4 samples per group. \*\*P<0.01. Bar plots  
545 show mean and standard deviation.

546

547 **Figure S5. Psyllium supplementation protects against beef protein diet-induced**  
548 **worsening of DSS-induced colitis.** WT specific pathogen free mice were fed beef protein (BP)  
549 or pea protein (BP) diets containing cellulose or BP diet containing psyllium (BP + Psyllium) for  
550 7 days. Mice were then administered 1% dextran sodium sulfate (DSS) and Disease Activity  
551 Index (DAI) was measured over 7 days (A) and colon length was measured on day 7 (B). Bar  
552 plots show mean and standard deviation.

553

## 554 **References**

555

- 556 1. Sartor RB, Wu GD. Roles for Intestinal Bacteria, Viruses, and Fungi in Pathogenesis of  
557 Inflammatory Bowel Diseases and Therapeutic Approaches. *Gastroenterology*.  
558 2017;152(2):327-39.e4.
- 559 2. Perler BK, Friedman ES, Wu GD. The role of the gut microbiota in the relationship  
560 between diet and human health. *Annual review of physiology*. 2023;85:449-68.
- 561 3. Lee D, Albenberg L, Compher C, Baldassano R, Piccoli D, Lewis JD, et al. Diet in the  
562 Pathogenesis and Treatment of Inflammatory Bowel Diseases. *Gastroenterology*.  
563 2015;148(6):1087-106.
- 564 4. Gleave A, Shah A, Tahir U, Blom J-J, Dong E, Patel A, et al. Using Diet to Treat  
565 Inflammatory Bowel Disease: A Systematic Review. *Official journal of the American College of*  
566 *Gastroenterology | ACG*. 2025;120(1).
- 567 5. Issokson K, Lee DY, Yarur AJ, Lewis JD, Suskind DL. The Role of Diet in Inflammatory  
568 Bowel Disease Onset, Disease Management, and Surgical Optimization. *Official journal of the*  
569 *American College of Gastroenterology | ACG*. 2025;120(1).
- 570 6. Hashash JG, Elkins J, Lewis JD, Binion DG. AGA Clinical Practice Update on Diet and  
571 Nutritional Therapies in Patients With Inflammatory Bowel Disease: Expert Review.  
572 *Gastroenterology*. 2024;166(3):521-32.
- 573 7. Kaplan GG, Ng SC. Understanding and Preventing the Global Increase of Inflammatory  
574 Bowel Disease. *Gastroenterology*. 2017;152(2):313-21.e2.
- 575 8. Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of  
576 inflammatory bowel disease. *Nature Reviews Gastroenterology & Hepatology*. 2021;18(1):56-  
577 66.
- 578 9. Kuenzig ME, Fung SG, Marderfeld L, Mak JWY, Kaplan GG, Ng SC, et al. Twenty-first  
579 Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease:  
580 Systematic Review. *Gastroenterology*. 2022;162(4):1147-59.e4.
- 581 10. Daniel CR, Cross AJ, Koebnick C, Sinha R. Trends in meat consumption in the USA.  
582 *Public Health Nutrition*. 2011;14(4):575-83.

- 583 11. Al Hasan SM, Saulam J, Mikami F, Kanda K, Ngatu NR, Yokoi H, et al. Trends in per  
584 Capita Food and Protein Availability at the National Level of the Southeast Asian Countries: An  
585 Analysis of the FAO's Food Balance Sheet Data from 1961 to 2018. *Nutrients*. 2022;14(3).  
586 12. Desai MS, Seekatz AM, Koropatkin NM, Kamada N, Hickey CA, Wolter M, et al. A  
587 Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances  
588 Pathogen Susceptibility. *Cell*. 2016;167(5):1339-53.e21.  
589 13. Hryckowian AJ, Van Treuren W, Smits SA, Davis NM, Gardner JO, Bouley DM, et al.  
590 Microbiota-accessible carbohydrates suppress *Clostridium difficile* infection in a murine model.  
591 *Nature Microbiology*. 2018;3(6):662-9.  
592 14. Llewellyn SR, Britton GJ, Contijoch EJ, Vennaro OH, Mortha A, Colombel J-F, et al.  
593 Interactions Between Diet and the Intestinal Microbiota Alter Intestinal Permeability and Colitis  
594 Severity in Mice. *Gastroenterology*. 2018;154(4):1037-46.e2.  
595 15. Kostovcikova K, Coufal S, Galanova N, Fajstova A, Hudcovic T, Kostovcik M, et al. Diet  
596 Rich in Animal Protein Promotes Pro-inflammatory Macrophage Response and Exacerbates  
597 Colitis in Mice. *Front Immunol*. 2019;10.  
598 16. Riva A, Kuzyk O, Forsberg E, Siuzdak G, Pfann C, Herbold C, et al. A fiber-deprived diet  
599 disturbs the fine-scale spatial architecture of the murine colon microbiome. *Nature*  
600 *Communications*. 2019;10(1):4366.  
601 17. Montrose DC, Nishiguchi R, Basu S, Staab HA, Zhou XK, Wang H, et al. Dietary  
602 Fructose Alters the Composition, Localization, and Metabolism of Gut Microbiota in Association  
603 With Worsening Colitis. *Cellular and Molecular Gastroenterology and Hepatology*.  
604 2021;11(2):525-50.  
605 18. Neumann M, Steimle A, Grant ET, Wolter M, Parrish A, Willieme S, et al. Deprivation of  
606 dietary fiber in specific-pathogen-free mice promotes susceptibility to the intestinal mucosal  
607 pathogen *Citrobacter rodentium*. *Gut Microbes*. 2021;13(1):1966263.  
608 19. Wolter M, Steimle A, Parrish A, Zimmer J, Desai Mahesh S. Dietary Modulation Alters  
609 Susceptibility to *Listeria monocytogenes* and *Salmonella Typhimurium* with or without a Gut  
610 Microbiota. *mSystems*. 2021;6(6):e00717-21.  
611 20. Shan Y, Lee M, Chang EB. The Gut Microbiome and Inflammatory Bowel Diseases.  
612 *Annu Rev Med* 2022;73:455-468.  
613 21. Pereira GV, Boudaud M, Wolter M, Alexander C, De Sciscio A, Grant ET, et al.  
614 Opposing diet, microbiome, and metabolite mechanisms regulate inflammatory bowel disease in  
615 a genetically susceptible host. *Cell Host & Microbe*. 2024;32(4):527-42.e9.  
616 22. Devkota S, Wang Y, Musch MW, Leone V, Fehlner-Peach H, Nadimpalli A, et al.  
617 Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in *Il10*<sup>-/-</sup> mice.  
618 *Nature*. 2012;487(7405):104-8.  
619 23. Lloyd-Price J, Arze C, Ananthakrishnan AN, Schirmer M, Avila-Pacheco J, Poon TW, et al.  
620 Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. *Nature*.  
621 2019;569(7758):655-62.  
622 24. Sinha SR, Haileselassie Y, Nguyen LP, Tropini C, Wang M, Becker LS, et al. Dysbiosis-  
623 Induced Secondary Bile Acid Deficiency Promotes Intestinal Inflammation. *Cell Host & Microbe*.  
624 2020;27(4):659-70.e5.  
625 25. Yang ZH, Liu F, Zhu XR, Suo FY, Jia ZJ, Yao SK. Altered profiles of fecal bile acids  
626 correlate with gut microbiota and inflammatory responses in patients with ulcerative colitis.  
627 *World J Gastroenterol*. 2021:June 28;7(4):3609-29.  
628 26. Joyce SA, Gahan CGM. Bile Acid Modifications at the Microbe-Host Interface: Potential  
629 for Nutraceutical and Pharmaceutical Interventions in Host Health. *Annual review of food*  
630 *science and technology*. 2016;7(1):313-33.  
631 27. Gray SM, Moss AD, Herzog JW, Kashiwagi S, Liu B, Young JB, et al. Mouse adaptation  
632 of human inflammatory bowel diseases microbiota enhances colonization efficiency and alters

- 633 microbiome aggressiveness depending on the recipient colonic inflammatory environment.  
634 *Microbiome*. 2024;12(1):147.
- 635 28. Png CW, Lindén SK, Gilshenan KS, Zoetendal EG, McSweeney CS, Sly LI, et al.  
636 Mucolytic Bacteria With Increased Prevalence in IBD Mucosa Augment In Vitro Utilization of  
637 Mucin by Other Bacteria. *Official journal of the American College of Gastroenterology | ACG*.  
638 2010;105(11).
- 639 29. Seregin SS, Golovchenko N, Schaf B, Chen J, Pudlo NA, Mitchell J, et al. NLRP6  
640 Protects IL10<sup>-/-</sup> Mice from Colitis by Limiting Colonization of *Akkermansia muciniphila*. *Cell*  
641 *Reports*. 2017;19(4):733-45.
- 642 30. Sugihara K, Kitamoto S, Saraithong P, Nagao-Kitamoto H, Hoostal M, McCarthy C, et al.  
643 Mucolytic bacteria license pathobionts to acquire host-derived nutrients during dietary nutrient  
644 restriction. *Cell Reports*. 2022;40(3).
- 645 31. Hoek Kristen L, McClanahan Kathleen G, Latour Yvonne L, Shealy N, Piazzuelo MB,  
646 Vallance Bruce A, et al. Turicibacterales protect mice from severe *Citrobacter rodentium*  
647 infection. *Infect Immun*. 2023;91(11):e00322-23.
- 648 32. Lynch JB, Gonzalez EL, Choy K, Faull KF, Jewell T, Arellano A, et al. Gut microbiota  
649 *Turicibacter* strains differentially modify bile acids and host lipids. *Nature Communications*.  
650 2023;14(1):3669.
- 651 33. Zhang W, Wang J, Zhang D, Liu H, Wang S, Wang Y, et al. Complete Genome  
652 Sequencing and Comparative Genome Characterization of *Lactobacillus johnsonii* ZLJ010, a  
653 Potential Probiotic With Health-Promoting Properties. *Frontiers in Genetics*. 2019;10.
- 654 34. Jia D-J-C, Wang Q-W, Hu Y-Y, He J-M, Ge Q-W, Qi Y-D, et al. *Lactobacillus johnsonii*  
655 alleviates colitis by TLR1/2-STAT3 mediated CD206<sup>+</sup> macrophages IL-10 activation. *Gut*  
656 *Microbes*. 2022;14(1):2145843.
- 657 35. Kastl A, Zong W, Gershuni VM, Friedman ES, Tanes C, Boateng A, et al. Dietary fiber-  
658 based regulation of bile salt hydrolase activity in the gut microbiota and its relevance to human  
659 disease. *Gut Microbes*. 2022;14(1):2083417.
- 660 36. Jantchou P, Morois S, Clavel-Chapelon F, Boutron-Ruault M-C, Carbonnel F. Animal  
661 Protein Intake and Risk of Inflammatory Bowel Disease: The E3N Prospective Study. *Official*  
662 *journal of the American College of Gastroenterology | ACG*. 2010;105(10).
- 663 37. Jowett SL, Seal CJ, Pearce MS, Phillips E, Gregory W, Barton JR, et al. Influence of  
664 dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. *Gut*.  
665 2004;53(10):1479.
- 666 38. Lees CW, Gros B, Kyle JA, Plevris N, Derikx L, Constantine-Cooke N, et al. 477c  
667 HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN  
668 ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY. *Gastroenterology*.  
669 2023;164(6):S-1571.
- 670 39. Jadhav A, Bajaj A, Xiao Y, Markandey M, Ahuja V, Kashyap PC. Role of Diet-  
671 Microbiome Interaction in Gastrointestinal Disorders and Strategies to Modulate Them with  
672 Microbiome-Targeted Therapies. *Annu Rev Nutr*. 2023;43:355-383.
- 673 40. Bibi S, De Sousa Moraes LF, Lebow N, Zhu M-J. Dietary Green Pea Protects against  
674 DSS-Induced Colitis in Mice Challenged with High-Fat Diet. *Nutrients*. 2017;9(5).
- 675 41. Ahn E, Jeong H, Kim E. Differential effects of various dietary proteins on dextran sulfate  
676 sodium-induced colitis in mice. *Nutr Res Pract*. 2022;16(6):700-15.
- 677 42. Chiang JYL, Ferrell JM. Bile Acids as Metabolic Regulators and Nutrient Sensors. *Annu*  
678 *Rev Nutr*. 2019;39:175-200.
- 679 43. Kubota H, Ishizawa M, Kodama M, Nagase Y, Kato S, Makishima M, et al. Vitamin D  
680 Receptor Mediates Attenuating Effect of Lithocholic Acid on Dextran Sulfate Sodium Induced  
681 Colitis in Mice. *International Journal of Molecular Sciences*. 2023;24(4).

- 682 44. Abdel-Razek EA-N, Mahmoud HM, Azouz AA. Management of ulcerative colitis by  
683 dichloroacetate: Impact on NFATC1/NLRP3/IL1B signaling based on bioinformatics analysis  
684 combined with in vivo experimental verification. *Inflammopharmacology*. 2024;32(1):667-82.
- 685 45. Wolter M, Grant ET, Boudaud M, Pudlo NA, Pereira GV, Eaton KA, et al. Diet-driven  
686 differential response of *Akkermansia muciniphila* modulates pathogen susceptibility. *Molecular*  
687 *Systems Biology*. 2024;20(6):596-625-.
- 688 46. Larabi AB, Masson HLP, Bäumlner AJ. Bile acids as modulators of gut microbiota  
689 composition and function. *Gut Microbes*. 2023;15(1):2172671.
- 690 47. van Best N, Rolle-Kampczyk U, Schaap FG, Basic M, Olde Damink SWM, Bleich A, et  
691 al. Bile acids drive the newborn's gut microbiota maturation. *Nature Communications*.  
692 2020;11(1):3692.
- 693 48. Islam KBMS, Fukiya S, Hagio M, Fujii N, Ishizuka S, Ooka T, et al. Bile Acid Is a Host  
694 Factor That Regulates the Composition of the Cecal Microbiota in Rats. *Gastroenterology*.  
695 2011;141(5):1773-81.
- 696 49. Tian YA-O, Gui W, Koo IA-O, Smith PB, Allman EA-O, Nichols RG, et al. The  
697 microbiome modulating activity of bile acids. *Gut Microbes*. 2020(Mar 5;11(4):979–996.).
- 698 50. Bretin A, Zou J, San Yeoh B, Ngo VL, Winer S, Winer DA, et al. Psyllium Fiber Protects  
699 Against Colitis Via Activation of Bile Acid Sensor Farnesoid X Receptor. *Cellular and Molecular*  
700 *Gastroenterology and Hepatology*. 2023;15(6):1421-42.
- 701 51. Sartor RB. Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative  
702 colitis. *Nature Clinical Practice Gastroenterology & Hepatology*. 2006;3(7):390-407.
- 703 52. Yang C, Merlin D. Unveiling Colitis: A Journey through the Dextran Sodium Sulfate-  
704 induced Model. *Inflammatory Bowel Diseases*. 2024;30(5):844-53.
- 705 53. Faith JJ, Ahern PP, Ridaura VK, Cheng J, Gordon JI. Identifying Gut Microbe–Host  
706 Phenotype Relationships Using Combinatorial Communities in Gnotobiotic Mice. *Science*  
707 *Translational Medicine*. 2014;6(220):220ra11-ra11.
- 708 54. Darfeuille-Michaud A, Neut C, Barnich N, Lederman E, Di Martino P, Desreumaux P, et  
709 al. Presence of adherent *Escherichia coli* strains in ileal mucosa of patients with Crohn's  
710 disease. *Gastroenterology*. 1998;115(6):1405-13.
- 711 55. Eun CS, Mishima Y, Wohlgemuth S, Liu B, Bower M, Carroll IM, et al. Induction of  
712 bacterial antigen-specific colitis by a simplified human microbiota consortium in gnotobiotic  
713 interleukin-10-/- mice. *Infect Immun*. 2014;82(6):2239-46.
- 714 56. Remke M, Groll T, Metzler T, Urbauer E, Kövilein J, Schnalzger T, et al.  
715 Histomorphological scoring of murine colitis models: A practical guide for the evaluation of colitis  
716 and colitis-associated cancer. *Experimental and Molecular Pathology*. 2024;140:104938.
- 717 57. Rath HC, Herfarth HH, Ikeda JS, Grenther WB, Hamm TE, Jr., Balish E, et al. Normal  
718 luminal bacteria, especially *Bacteroides* species, mediate chronic colitis, gastritis, and arthritis in  
719 HLA-B27/human beta2 microglobulin transgenic rats. *J Clin Invest*. 1996;98(4):945-53.
- 720 58. Chassaing B, Srinivasan G, Delgado MA, Young AN, Gewirtz AT, Vijay-Kumar M. Fecal  
721 Lipocalin 2, a Sensitive and Broadly Dynamic Non-Invasive Biomarker for Intestinal  
722 Inflammation. *PLoS One*. 2012;7(9):e44328.
- 723 59. Bai JDK, Saha S, Wood MC, Chen B, Li J, Dow LE, et al. Serine Supports Epithelial and  
724 Immune Cell Function in Colitis. *The American Journal of Pathology*. 2024;194(6):927-40.
- 725 60. Derrien M, van Baarlen P, Hooiveld G, Norin E, Muller M, de Vos W. Modulation of  
726 Mucosal Immune Response, Tolerance, and Proliferation in Mice Colonized by the Mucin-  
727 Degrader *Akkermansia muciniphila*. *Front Microbiol*. 2011;2.
- 728 61. Chetnik K, Benedetti E, Gomari DP, Schweickart A, Batra R, Buyukozkan M, et al.  
729 maplet: an extensible R toolbox for modular and reproducible metabolomics pipelines.  
730 *Bioinformatics*. 2022;38(4):1168-70.
- 731




Figure 1






Figure 3










Figure 4

**A****B**

**A**
 *Akkermansia muciniphila*
 *Clostridium disporicum*
 *Turicibacter sanguinis*
 *Lactobacillus johnsonii*
 *Bacteroides acidifaciens*
 Other
**B**
 *Akkermansia muciniphila*
 *Clostridium disporicum*
 *Turicibacter sanguinis*
 *Lactobacillus johnsonii*
 *Bacteroides acidifaciens*
 Other








Figure S3





**A****B**

Figure S5

Table S1. Experimental Diet Formulations

	<b>Beef</b>	<b>Casein</b>	<b>Egg</b>	<b>Pea</b>	<b>Soy</b>	<b>Beef + Psyllium</b>
<b>Ingredient</b>	gm	gm	gm	gm	gm	gm
Casein	0	200	0	0	0	0
Soy Protein, Supro 661	0	0	0	0	202.3	0
Egg Whites	0	0	210.9	0	0	0
Beef Protein Isolate, Sigma	226.9	0	0	0	0	226.9
Pea Protein, Pure Bulk	0	0	0	209.1	0	0
L-Cystine	3	3	3	3	3	3
Corn Starch	398.486	397.486	389.286	398.486	395.486	385.329
Maltodextrin 10	132	132	132	132	132	132
Sucrose	100	100	100	100	100	100
Psyllium	0	0	0	0	0	52.63
Cellulose, BW200	50	50	50	50	50	0
Soybean Oil	70.8	70	70.2	51.8	63	70.8
t-Butylhydroquinone	0.014	0.014	0.014	0.014	0.014	0.014
Mineral Mix S10022G	0	0	0	0	0	0
Mineral Mix S10001A	17.5	17.5	17.5	17.5	17.5	17.5
Calcium Phosphate, Dibasic	17.5	17.5	17.5	17.5	17.5	17.5
Calcium Carbonate	0	0	0	0	0	0
Potassium Citrate, Monohydrate	0	0	0	0	0	0
Potassium Phosphate, Monobasic	0	0	0	0	0	0
Sodium Chloride	0	20.2	12.9	19.3	19.2	0
Vitamin Mix V10037	0	0	0	0	0	0
Vitamin Mix V10001	10	10	10	10	10	10
Biotin, 0.1%	0	0	0.4	0	0	0
Choline Bitartrate	2.5	2.5	2.5	2.5	2.5	2.5
<b>Total</b>	<b>1028.7</b>	<b>1020.2</b>	<b>1016.2</b>	<b>1011.2</b>	<b>1012.5</b>	<b>1018.2</b>
Protein (gm)	177.0	177.0	177.0	177.0	177.0	177.0
Carbohydrate (gm)	640.5	640.5	640.5	640.5	640.5	640.5
Fat (gm)	71.0	71.0	71.0	71.0	71.0	71.0
Fiber (gm)	50.0	50.0	50.0	50.0	50.0	52.63
Protein (kcal)	708.1	708.0	708.0	707.9	707.9	708.1
Carbohydrate (kcal)	2561.9	2561.9	2561.9	2561.9	2561.8	2561.9
Fat (kcal)	639.2	638.6	639.4	639.3	639.3	639.2
Total	3909.3	3908.6	3909.3	3909.2	3909.0	3909.3
Protein (gm%)	17.2	17.3	17.4	17.5	17.5	17.2
Carbohydrate (gm%)	62.3	62.8	63.0	63.3	63.3	63.0
Fat (gm%)	6.9	7.0	7.0	7.0	7.0	6.9
Protein (kcal%)	18.1	18.1	18.1	18.1	18.1	18.1
Carbohydrate (kcal%)	65.5	65.5	65.5	65.5	65.5	65.5
Fat (kcal%)	16.4	16.3	16.4	16.4	16.4	16.4
Sodium (g/kg)	8.8	8.8	8.8	8.8	8.8	8.8
kcal/gm	3.8	3.8	3.8	3.9	3.9	3.8

Table S2. Primer Sequences

Murine Targets		
Gene	Type	Sequence (5'-3')
B-actin	Forward	GGCTGTATTCCCCTCCATCG
	Reverse	CCAGTTGGTAACAATGCCATGT
Il1b	Forward	TGGGCCTCAAAGGAAAGAAT
	Reverse	CAGGCTTGTGCTCTGCTTGT
Tnfa	Forward	ACCCTCACACTCAGATCATCTTCTC
	Reverse	TGAGATCCATGCCGTTGG
Bacterial PCR Targets		
<i>Akkermansia muciniphila</i>	Akk-16S-F	GATAGTACCACAAGAGGAAGAGACG
	Akk-16S-R	TTCCCCCTCCATTACTCTAGTCTC
<i>Lactobacillus johnsonii</i>	Ljohn-16S-F	GCCTAGATGATTTTAGTGCTTGCAC
	Ljohn-16S-R	AGCAGAACCATCTTTCAAACCTCTAGA
<i>Turicibacter sanguinis</i>	Turi-16S-F	TGTGACGGTACCTTATGAGAAAGC
	Turi-16S-R	GTTGACCAGTTTCCAATGACCCTC
Universal 16s Primer	Forward	ACTCCTACGGGAGGCAGCAG
	Reverse	ATTACCGCGGCTGCTGG
To amplify EER	Forward	U341F 5'-CCTACGGGRSGCAGCAG-3'
	Reverse	UA1406R 5'-ACGGGCGGTGWGTRCAA-3'